Let's Get Started

Analysis

Advantis Corporation (OTCMKTS:ADVT) Rolls Out Cannabis Products for Pain Relief

Advantis Corporation (OTCMKTS:ADVT) Rolls Out Cannabis Products for Pain Relief

Feb 22, 2017

Advantis Corporation (OTCMKTS:ADVT) shares rose 13.56% to $0.0335 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.03. The company has a market cap of $13.96 million at 465.48 million shares outstanding.

Advantis Corporation is a company that is focused on helping people take control of their health and pain management needs. It does this through partnerships innovative companies in the nutraceutical and alternative health care industries, making the company uniquely positioned to provide the guidance and support to assist in delivering products and services that address the needs of these individuals. Their strategy involves acquiring ownership in developing companies and providing consultation to improve product lines, expand distribution channels, and heighten brand value. Advantis concentrates on healthcare and pain management sectors that forecast staggering growth, identifying partners that possess the potential to capitalize on this trend.

In a press release yesterday, Advantis Corporation announced that it begins distribution of topical cannabis roll-on and Tinctures to treat pain conditions. In particular, Elixicure is a line of CBD dominant products used to treat pain without the psychoactive effects associated with THC.  Its pain relief roll-onis specially formulated, using the extract of the cannabis plant, which contains the principal cannabinoid CBD while the pain cream includes over 90% Certified Organic ingredients and is specially formulated with Counter-Irritants to block pain receptors and Salicylic Acids to provide a deep penetrating Aspirin-like relief.

Elixicure utilizes the purest, pharmaceutically derived essential oils and active ingredients to create products that are superior in quality than those available in the marketplace today, and we are very excited to add them to our rapidly growing portfolio of products,” said Advantis Corporation CEO Christopher Swartz in a recent press conference.

The company has been on an all-out media blitz to provide exposure to deliver attention to their progress and product lines. They have also tapped UFC Legend Kimo Leopoldo as a brand ambassador since many high-profile fighters have been lobbying to make CBD remedies legal.

My passion for fighting has been a painful one. The day-to-day grind in the gym as well as the battles in The Octagon left me with aches and pains. The doctors prescribe medicines that may help with this pain, but the side effects from those medicines outweigh the benefits. The Elixicure line of products have relieved my pain with zero side effects,” said Kimo.

In a previous announcement CEO Swartz hinted that “revenue is about to explode” as the company has several efforts lined up for 2017. He added that the company is poised to reach its highest revenue ever for the year and that this momentum can be sustained in the foreseeable future.

We have seen the problem with chronic pain conditions increase exponentially and with that, opiate misuse and addiction as well. I have personally seen all this happen and have observed (too many times) people whom have lost hope,” Swartz further explained, “I have been passionate about creating solutions to effectively treat the masses without the negative side effects associated with opioids. Elixcure is the answer, and we are excited beyond belief to share this remedy with everyone in need.”

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more
Don’t Miss This Bullish Run on OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

Don’t Miss This Bullish Run on OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

Feb 21, 2017

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) shares rose 36.57% on Friday to $0.915 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.95. The company has a market cap of $128.82 million at 135.31 million shares outstanding.

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. As such, it is engaged in the research and development of cannabis-based medical products for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications.

The company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. It was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device, and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder migraines and a delivery system.

Last week, OWC Pharmaceutical Corp announced that it would be presenting at the Wall Street Conference, which will be held at the Hilton Doubletree Hotel and Conference Center in Deerfield Beach, Boca Raton, Florida, on Wednesday, March 1, 2017. This premiere conference in the venture capital arena and small-cap marketplace includes industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, who attend to discuss significant trends in the financial markets.

The Wall Street Conference is one of the leading conferences for small-cap investors and OWC is excited to be a part of it. OWC continues to make significant progress in the research and development of cannabis-centric medical treatments, specifically with our psoriasis cream, which is being readied for the U.S. and European markets.  We are focused on having our products on the shelves in the MMJ states this year. I am very much looking forward to discussing the Company with conference attendees,” remarked Ziv Turner, OWC Pharmaceutical Corp’s VP Business development and Managing Director of One World Cannabis.

Member of the company’s Advisory Board, Jeffrey Friedland, is a featured speaker at the Conference and is expected to discuss the opportunities for public company investments in the cannabis sector, and the positive impact that Israeli science and companies are having on the U.S. and Canadian cannabis markets. He is also CEO of Intiva Inc., which was an early-stage investor in OWC, and the author of Marijuana: The World‘s Most Misunderstood Plant.

The legal cannabis market has expanded considerably over the past two years, generating significant and growing investor interest. However, there are only a handful of publicly-traded companies focused on cannabinoid-based, pharmaceutical development and a true scientific approach to product development. I intend to discuss what I see as the publicly-traded cannabis opportunities at the Conference,” Friedland noted.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more
How Canopy Growth Corp (TSE:WEED) Shares Reacted to Earnings

How Canopy Growth Corp (TSE:WEED) Shares Reacted to Earnings

Feb 15, 2017

Canopy Growth Corp (TSE:WEED) shares were down 8.08% to $11.95 on Tuesday and flat in after-hours trading. Share prices have been trading in a 52-week range of $2.70 to $17.86. The company has a market cap of $1.99 billion at 159.13 million shares outstanding.

Formerly known as Tweed Marijuana Inc, Canopy Growth Corp is a diversified cannabis company. Through its subsidiaries Tweed Inc. (Tweed), Bedrocan Canada Inc. (Bedrocan) and Tweed Farms Inc. (Tweed Farms), is engaged in the business of producing and selling legal marijuana in the Canadian medical market. It is also focusing on producing and selling marijuana in the recreational market in Canada. Its core brands are Tweed and Bedrocan.

Tweed is a licensed producer of medical marijuana. Tweed’s commercial license covers approximately 168,000 square feet of its Smiths Falls facility and allows Tweed to produce and sell approximately 3,540 kilograms of medical marijuana per year. Tweed’s built-out production capacity is over 10 climate controlled indoor growing rooms. Bedrocan is a medical-grade cannabis. Bedrocan’s over 52,000 square feet production facility in Toronto, Ontario is licensed, and includes over 30 vegetative and growing rooms, and over three dispensing rooms.

Canopy Growth Corp recently printed its quarterly earnings figures and investors seem unimpressed. The company reported over 29,000 registered patients at December 31, 2016 compared to over 8,000 at December 31, 2015, representing a greater than 260% increase. It made revenue of $9.8 million, which amounts to a 15% increase over the second quarter in the fiscal year 2017 and 180% increase over the prior year period.

However, the company admitted that revenue growth was limited by the product mix available for sale, as supply was limited in the quarter due to rigorous procedures to fully test the record harvest and approve the extensive product released for sale subsequent to quarter end. Still, it was able to harvest a record 5,264 kilograms compared to 1,711 kilograms in the second quarter fiscal year 2017, which amounts to a 208% increase.

The third quarter provided new opportunities and challenges for our business, with demand largely exceeding supply throughout the quarter,” said Bruce Linton, Chairman & CEO of Canopy Growth Corp. “A function of our growing patient base, the time required to move from a record harvest to sale, and an extensive phenotyping exercise to establish breeding stock and further elevate our product offering all resulted in constrained product available for sale during the quarter. The successful late-quarter harvest of the Tweed Farms facility running at full capacity has begun to ease supply constraints while at the same time we have introduced a new diversity of product into our online store under the Tweed, Leafs By Snoop and DNA Genetics banners, driving strong sales this month.”

Other developments over the period included the acquisition of a 472,000 square foot and 42 acre property at 1 Hershey Drive, Smiths Falls, Ontario on January 13, 2017. This is on top of the acquisition of  Mettrum Health Corp on January 31, 2017 and the change in the TSX trading symbol from CGC to WEED early this month.

We continued to push the boundaries of our business during the quarter through multiple strategic accomplishments that will help drive our future growth. We worked to strengthen our market position in Canada with our move to acquire Mettrum and the acquisition of Vert Cannabis to establish a unique brand presence in Quebec. We also established a base of operations in Germany, a strategic future market for Canopy, with the purchase of cannabis distributor, MedCann GMBH,” added Linton.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more
Why Sycamore Entertainment Group Inc (OTCMKTS:SEGI) Shares Slumped

Why Sycamore Entertainment Group Inc (OTCMKTS:SEGI) Shares Slumped

Feb 13, 2017

Sycamore Entertainment Group Inc (OTCMKTS:SEGI) shares dropped 42.86% to $0.00040 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.00. The company has a market cap of $971K at 1.39 billion shares outstanding.

Sycamore Entertainment Group Inc is an independent film marketing and distribution company that specializes in the acquisition, distribution and development of marketing campaigns. It focuses on participating in various other streams related to filmed entertainment content distribution, as well as various other activities related to funding the print and advertising of acquired feature films. Its film marketing and distribution operations include film acquisitions, publicity, print advertising, billboard advertising, film distribution and online marketing.

The company also offers services, including acquiring films; publicity and public relations, and online content writing and search engine optimization services. It provides distribution services for release commercial films. It represents independent film companies that create domestic and foreign feature films. Its operations include Film Library Development, Distribution, Print and Advertising Fund, and Production.

Just last week, Sycamore Entertainment Group announced that it has executed a “film rights purchase agreement” with top Hollywood producers.

We are excited to be working some of the best talents in Hollywood,” says Edward Sylvan, CEO of Sycamore Entertainment Group. “Our arrangement with LDJ Capital called for us to bring ‘best in class’ projects to the table, I feel we are accomplishing these objectives. We are looking forward to the time when we are able discuss the project in more detail. With the working capital in hand we are in the best position to increase shareholder value by spending on corporate marketing and executing on our lineup of film and TV projects.”

This contributed to more than 70% gains in Sycamore Entertainment Group shares at the start of the week but more than half of this was given back when it announced a self-imposed share issuance lockout.

The lack of trust in OTC issuers by Penny Stock traders has been a major roadblock to issuers when trying to raise the necessary working capital needed to grow their business. Sycamore is taking a first step in restoring that trust with its shareholders,” the company statement indicated. “Effective immediately, we will apply a self-imposed share structure lockout for a minimum of 60 days. During that time, there will be no issuances of new shares, nor will there be any increase to the authorized share capital. It is my opinion, that the current issued and outstanding is ideal to encourage liquidity and allows investors of all sizes to participate in our market.”

In effect, Sycamore Entertainment Group will not be engaging in any reverse split at any time whatsoever in order to provide traders and investors with the confidence that they can participate in the market and not have the share value be eroded due to unnecessary dilution.

We would like to send a message loud and clear that we support the trading and investing community and that we share common goals. The sooner that we can align our interests the faster we can move the company ahead. The new laws allow us to take the power away from dilutive financing options and places it back into the hands of the traders and shareholders who continue to support what we do,” it concluded.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more
Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares

Here’s Who Just Picked Up Natera Inc. (NASDAQ:NTRA) Shares

Feb 9, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Natera Inc. (NASDAQ:NTRA) reported that Claremont Creek Ventures L P. has picked up 7,020,856 of common stock as of 2017-02-09.

The acquisition brings the aggregate amount owned by Claremont Creek Ventures L P. to a total of 7,020,856 representing a 13.4% stake in the company.

For those not familiar with the company, Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).

A glance at Natera Inc. (NASDAQ:NTRA)’s key stats reveals a current market capitalization of 490.34 million based on 52.38 million shares outstanding and a price at last close of $9.31 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-06-19, Steuart picked up 66,621 at a purchase price of $11.94. This brings their total holding to 83,752 as of the date of the filing.

On the sell side, the most recent transaction saw Rosenman unload 1,850 shares at a sale price of $8.95. This brings their total holding to 34,755.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Natera Inc. (NASDAQ:NTRA) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

read more
Why Pharmacyte Biotech Inc (OTCMKTS:PMCB) Shares Fell 13%

Why Pharmacyte Biotech Inc (OTCMKTS:PMCB) Shares Fell 13%

Feb 9, 2017

Pharmacyte Biotech Inc (OTCMKTS:PMCB) shares were down 13.04% on Wednesday but recovered 1.39% in after-hours trading. Share prices have been trading in a 52-week range of $0.02 to $0.17. The company has a market cap of $96.95 million at 849.90 million shares outstanding.

Pharmacyte Biotech Inc is a clinical-stage biotechnology company that is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. This Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed.

Aside from that, Pharmacyte Biotech is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.

Pharmacyte Biotech recently announced that an audio recording of the company’s shareholder call, which was held on February 7 is now available for playback.

I would like to thank everyone who listened to our shareholder call update yesterday. I would also like to apologize for the call abruptly cutting off during the question and answer session. The call stopped at the one-hour mark. That has never happened before. The call was scheduled to continue for one and a half hours. Since we wanted to answer all of the questions that were submitted, we have recorded the balance of the questions and answers,” explained Pharmacyte Biotech CEO Kenneth Waggoner.

The audio recording with remaining questions and answers of the shareholder call can be found here: https://fccdl.in/b0lcv21IV.

Earlier in the year, Pharmacyte Biotech announced its plans to initiate a clinical trial in pancreatic cancer, involving the application of Cell-in-a-Box to go head to head with the current gold standard in pancreatic cancer treatment called gemcitabine. The company has completed a pre-IND meeting with the FDA so it could proceed with the Phase 1 of treatment soon. Once this announcement is made, further bullish upside is expected for the company. This month, the company was granted orphan drug designation for pancreatic cancer treatment.

Pharmacyte Biotech has made a huge upside breakout from its slow downtrend for the most part of 2016, signaling further upside for the stock. Volume has been subdued since the bullish break, leading to some profit-taking and consolidation, but the bullish flag remains intact even as price has pulled back. Buyers could simply be waiting for more updates from the company before taking the stock further north, possibly for another test of the $0.15 mark in the near-term then onto $0.20 and beyond.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

 

read more
Here’s Who Just Picked Up IHS Markit Ltd. (NASDAQ:INFO) Shares

Here’s Who Just Picked Up IHS Markit Ltd. (NASDAQ:INFO) Shares

Feb 8, 2017

In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), IHS Markit Ltd. (NASDAQ:INFO) reported that Artisan Partners Limited Partnership has picked up 43,393,572 of common stock as of 2017-02-03.

The acquisition brings the aggregate amount owned by Artisan Partners Limited Partnership to a total of 43,393,572 representing a 10.7% stake in the company.

For those not familiar with the company, IHS Markit Ltd, formerly Markit Ltd., provides critical information, analytics and solutions for the industries and markets that drive economies worldwide. The Company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights. The Company has approximately 50,000 business and government customers, including 80 percent of the Fortune Global 500 and financial institutions.

A glance at IHS Markit Ltd. (NASDAQ:INFO)’s key stats reveals a current market capitalization of 16.04 billion based on 406.91 million shares outstanding and a price at last close of $39.54 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2017-01-19, Kelly picked up 10,000 at a purchase price of $38.62. This brings their total holding to 67,964 as of the date of the filing.

On the sell side, the most recent transaction saw Hyatt unload 14,000 shares at a sale price of $39.38. This brings their total holding to 353,892.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on IHS Markit Ltd. (NASDAQ:INFO). as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.

 

 

 

read more
One Bullish Prospect After Another for Zerez Holdings Inc (OTCMKTS:ZRZH)

One Bullish Prospect After Another for Zerez Holdings Inc (OTCMKTS:ZRZH)

Feb 7, 2017

Zerez Holdings Inc (OTCMKTS:ZRZH) shares were up 18.18% on Tuesday to $0.0449 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.06. The company has a market cap of $211 million at 5.57 billion shares outstanding.

Zerez Holdings Inc is a public equity corporation that is focused on the advanced agriculture and cannabis industries with plans to grow through acquisition, strategic alliances, and proprietary intellectual property. The company’s wholly owned subsidiary Next Generation Farming provides turnkey commercial greenhouse and automation systems that improve yields and decrease water consumption for cultivators of organic food and cannabis crops.

In a press release yesterday, Zerez Holdings Inc reported that  its subsidiary Next Generation Farming Inc has signed its Co-Marketing partner Sweet Leaf Hydroponics to a wholesale purchase contract for a minimum of $1 million dollars worth of NextGen’s “SMART by Design” line of advanced and automated greenhouse systems by the end of the year. On top of this, Sweet Leaf has also ordered 2 30ft. x 24ft. production models to be built as walk-thru demonstration facilities at each of their sales locations.

“It was imperative that we enlisted the feedback about our marketing strategy, product designs, configurations, pricing and overall sales and support strategy with Jay and our extended team at Sweet Leaf Hydro. They sell millions in revenue to thousands of clients and we wanted to leave no stone unturned before our upcoming launch. Obviously we have a good plan for Jay to make such a strong minimum sales commitment to us,” said John Taylor and Don Smith of Zerez Holdings Inc.

For Jay DeSalvatore, president of Sweet Leaf Hydroponics, the companies are in full alignment and are confident that they can easily re-sell a million dollars of their products by the end of the year. Sweet Leaf has hundreds of regular customers and lots of immediate greenhouse sales opportunities.

“The data we continue to see is that the smart greenhouse marketplace is worth a minimum of $6 billion in 2017. Although we see most of our sales being on the commercial scale, with multi-faceted customer relationships, we have created some unique and surprising products that will be available for immediate purchase when we launch. We intend to smartly capture our profitable share of this market. If Zerez Holdings and Next Generation Farming earn just 10-20% market share, that translates into potential revenues of $600 Million to $1.2 billion annually. Obviously, we are ramping our business quickly, and we are confident we can handle that level of growth when it comes,” Taylor added.

In January, Zerez Holdings Inc announced that it has sold another “SMART by Design” greenhouse system to its first repeat client, a Northern California Cannabis cultivation company, from earlier in the month.

“When a client comes back and orders from you again that is our definition of consumer confidence. We are very pleased that the trust, confidence and great working relationship with our customer has resulted in a second order in less than 10 days,” Taylor shared.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more
Why Earth Science Tech Inc (OTCMKTS:ETST) Shares Rose Nearly 30%

Why Earth Science Tech Inc (OTCMKTS:ETST) Shares Rose Nearly 30%

Feb 7, 2017

Earth Science Tech Inc (OTCMKTS:ETST) shares were up 27.78% to $1.38 on Monday to $1.38 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.18 to $1.70. The company has a market cap of $55.85 million at 40.47 million shares outstanding.

Earth Science Tech Inc is a biotechnology company that is focused on nutraceuticals and bioceuticals for use in various industries, such as health, wellness, nutritional supplements, cosmetic and alternative medicine to manage illnesses and the quality of life for consumers around the world. It sells its products through its retail store located in Coral Gables, Florida, and through the Internet.

The company is also focused on delivering nutritional and dietary supplements that help with treating symptoms, such as chronic pain, joint pain, inflammation, seizures, high blood pressure, memory loss, depression, weight management, nausea and aging. This may include products, such as vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. These products will be in various formulations and delivery forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs.

In a press release this week, Earth Science Tech Inc announced that itsnew wholly owned subsidiary, Cannabis Therapeutics, Inc. will be releasing new Cannabinoid-based Drugs and Nutraceuticals. In particular, Cannabis Therapeutics will begin by inventing & launching 2 new cannabinoid-based pharmaceutical drugs and 3 new advanced cannabinoid-based nutraceutical products using Earth Science Tech’s existing Cannabis CBD Patent, IP, invention, technology and future technology.

“I am very enthusiastic about Cannabis Therapeutics position in the cannabis industry to become a leader in cannabinoid research and development. Our imminent new developments and efforts have the potential to expedite our numerous upcoming cannabis cannabinoid-based therapeutic products to help aid people with certain conditions and disorders worldwide, in the later part of 2017. We are focused on cannabinoid-based therapeutic drugs, functional foods and nutraceuticals (retail consumer markets worldwide). We look to announce later this week a New Scientific Advisory Board which will include myself, Dr. Michel Aube, as the Chairman of the Advisory board to Cannabis Therapeutics, Inc. as well as other World Class Scientists,” said Dr. Michael Aube, CEO of Earth Science Tech Inc.

Cannabis Therapeutics plans on distinguishing itself from many competing cannabinoid-focused biotechnology companies with its competent capital apportionment. Its board of directors and upcoming new scientific advisory board intends to broaden the current operations of the Cannabis Therapeutics to include a variety of other products, solutions, laboratories and expertise. Its goal is to discover solutions for conditions for which there is presently no effective treatment as well as other medical disorders with the application of known and novel cannabis cannabinoid-based products.

ETST is extremely fortunate to have attracted world leaders to our executive leadership team and Board of Advisors. All of them are contributing their passion, time and expertise to the development of Cannabis Therapeutics unique cannabinoid-based products and solutions. Cannabis Therapeutics goal is to help advance the cannabis-cannabinoid healthcare industry and have a positive impact on the wellbeing of humans worldwide” Dr. Aube continued.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.

read more